verified SJR 1,348 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom · SAGE Publications Inc.

workspace_premium Q1 — Orthopedics and Sports Medicine lock Subscription

Therapeutic Advances in Musculoskeletal Disease

Therapeutic Advances in Musculoskeletal Disease is a journal indexed in SJR in Orthopedics and Sports Medicine with an H index of 54. It has a price of 4375 €. It has an SJR impact factor of 1,348 and it has a best quartile of Q1. It has an SJR impact factor of 1,348.

ISSN: 1759-720X

Publisher: SAGE Publications Inc.

Category: Orthopedics and Sports Medicine

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,348 Q1

H-index 54

Acceptance rate pie_chart

33%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

4.375 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,348

H-index

Docs (year)

Docs 3y

264

Total refs

3263

Cites 3y

1113

Citable 3y

260

Cites/Doc 2y

4.14

Ref/Doc

57.25

Immediate OA

4375 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence

Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis

Distal biceps reconstruction 13 years post-injury

Disease-modifying antirheumatic drugs improve cardiovascular autonomic neuropathy in psoriatic arthritis

Diagnosis and treatment of the idiopathic inflammatory myopathies

Denosumab in postmenopausal osteoporosis: what the clinician needs to know

Cutaneous Side Effects of Antiosteoporosis Treatments

Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions

Cartilage regeneration for treatment of osteoarthritis: a paradigm for nonsurgical intervention

Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis

Bone health in HIV and hepatitis B or C infections

Bisphosphonate drug holiday: who, when and how long

SHOW MORE ARTICLES

Biologicals and bone loss

A case of missed ocular torticollis

Biologic agents in rheumatoid arthritis: temporal trend of incremental benefits

Belimumab in systemic lupus erythematosus: a perspective review

Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness

B-cell survival factors in autoimmune rheumatic disorders

Assessment of synovitis to predict bone erosions in rheumatoid arthritis

Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases

Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture

Apremilast in the treatment of psoriatic arthritis: a perspective review

Analytical considerations for the biochemical assessment of vitamin D status

An update on the management of antiphospholipid syndrome

FAQs

Therapeutic Advances in Musculoskeletal Disease has an SJR of 1,348 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 4375 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Therapeutic Advances in Musculoskeletal Disease is 33%.

Therapeutic Advances in Musculoskeletal Disease

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Therapeutic Advances in Musculoskeletal Disease?

What is the APC / publication cost?

What is the acceptance rate?